Pharmacologic Substance – Page 120

Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

11 months ago talkbio0Tagged Disease remission, Effectiveness, guselkumab, Inflammatory Bowel Diseases, J&J, Johnson & Johnson, Maintenance, Phase 3 Clinical Trials, Safety, Tremfya, Ulcerative Colitis

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.

EU Upholds Approval of PTC Therapeutics’ Duchenne Muscular Dystrophy Treatment

11 months ago talkbio0Tagged Approved, Duchenne, EU, factor IX, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Rejection (Psychology)

EU, PTC Therapeutics, Duchenne Muscular Dystrophy (DMD), treatment, approval, rejection, committee.

Translarna by PTC Therapeutics: Awaiting Another EU Regulatory Review for Muscular Dystrophy Treatment

11 months ago talkbio0Tagged ataluren, disease treatment, EU, European Medicines Agency, factor IX, Infrequent, Muscular Dystrophy, Muscular Dystrophy, Duchenne, regulatory approval, Translarna

PTC Therapeutics, Translarna, muscular dystrophy, EU review, regulatory approval, Duchenne muscular dystrophy (DMD), European Medicines Agency (EMA), ataluren, rare disease treatment.

AstraZeneca Ordered to Pay Pfizer Over $107 Million in Tagrisso Patent Infringement Case

11 months ago talkbio0Tagged AstraZeneca, infringement, jury, Legal patent, Malignant neoplasm of lung, Pfizer, Tagrisso, Tissue damage

AstraZeneca, Pfizer, Tagrisso, patent infringement, jury verdict, damages, lung cancer treatment

FDA Revokes Accelerated Approval of Helsinn’s Cancer Drug at Company’s Request

11 months ago talkbio0Tagged Accelerated, Antineoplastic Agents, Approved, Clinical Trials, Helsinn, patient safety, regulatory, United States Food and Drug Administration

FDA, Helsinn, accelerated approval, cancer drug, company request, drug withdrawal, regulatory decision, clinical trials, patient safety.

Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine

11 months ago talkbio0Tagged BioNTech, COVID19 (disease), Drug Industry, EPO, EU, European (ethnic group), Intellectual Property, Legal patent, Moderna, mRNA technology, Pfizer, Vaccines

Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.

Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering

11 months ago talkbio0Tagged clinical-stage, expansion, IPO, mental health, nervous system disorder, Neuroscience discipline, Rapport

Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health

AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

11 months ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, expansion, Facility (object), Generalized, innovation, Investments, Singapore

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.